Offering the benefits of real-time collaboration and integrated connectivity, the portable ultrasound device may be utilized in a variety of clinical settings ranging from cardiology to obstetrics and gynecology.
The Philips Ultrasound 5000 Compact Series, which reportedly facilitates real-time collaboration and streamlined workflows, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Philips noted the portable device provides a combination of enhanced image quality and remote consultation capability (via Philips Ultrasound Collaboration Live tele-ultrasound) that facilitates clinical decision support with mobile efficiency. In addition to general imaging and utility in the obstetrics and gynecology fields, Philips said the Ultrasound 5000 Compact Series enables timely assessments in cardiology and point-of-care ultrasonography.
“Globally, clinicians are faced with increasing pressures to deliver higher patient throughput for quick, confident diagnoses via ultrasound exams while receiving more and more requests to perform rapid ultrasound exams at the bedside,” noted Matthijs Groot Wassink, the general manager of Point-of-Care Ultrasound at Philips. “Until now, portable ultrasound systems have typically meant decreased performance, lack of advanced features, and lower grade image quality. With this clearance for our next-generation portable Philips Ultrasound 5000 Compact Series, clinicians now have the ability to make quicker and more confident diagnoses.”
In order to facilitate consistency and efficiency with use of the Ultrasound 5000 Compact Series, Philips said the new portable device offers the same features, touch screens and user interfaces as the company’s EPIQ and Affiniti ultrasound systems.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.